The use of artificial intelligence (AI) in the pharmaceutical sector is transforming drug discovery, development, and regulatory approval processes, creating significant opportunities for the emerging techbio industry. According to a report by Tecknoworks, the global AI in pharmaceuticals market was valued at $1.8 billion in 2023 and is expected to grow substantially to $13.1 billion by 2034, representing a compound annual growth rate (CAGR) of 18.8% between 2024 and 2034.
The company we are profiling today is Caris Life Sciences, Inc. (CAI), a patient-centric AI TechBio company that uses molecular data and artificial intelligence/machine learning algorithms to advance precision medicine, with a primary focus on oncology and services for clinical, academic, and biopharma markets.
For comments and feedback contact: editorial@rttnews.com
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.